



MEDIA RELEASE

May 2016

David Sinclair, Ph.D. joins Jupiter Orphan Therapeutics, Inc.

Jupiter Orphan Therapeutics, Inc. (JOT) today announced that world renowned scientist David Sinclair, Ph.D. joined JOT as Co-Chairman of its Scientific Advisory Board (SAB).

“This is a fantastic addition to our company and Dr. Sinclair’s knowledge, network and reputation is very valuable to a small company like Jupiter Orphan Therapeutics” stated JOT CEO, Christer Rosén.

Dr. Sinclair was contacted by his fellow scientists, Prof Martin Delatycki from Murdoch Childrens Research Institute, Australia and JOT CSO Dr. Claes Wahlestedt, who informed him of the resveratrol JOTROL product that was developed by JOT.

Dr. Sinclair, who is one of the leading scientists in the world regarding resveratrol’s benefit in various disease areas, expressed his enthusiasm of the test results achieved with JOTROL and immediately accepted a position as Co-Chairman of the JOT SAB.

Dr. Sinclair stated “

David Sinclair, Ph.D. is the Co-Chairman of the JOT Scientific Advisory Board at Jupiter Orphan Therapeutics. He is currently the Co-Director of the Paul F. Glenn Center for the Biology of Aging as well as the Professor of Genetics at Harvard Medical School. Dr. Sinclair has co-founded 8 biotechnology companies, four of which have gone public, including Sirtris Pharmaceuticals which was sold to GSK for \$720M. He has 170 publications and 40 patents. Dr. Sinclair co-discovered Sirtuin activating compounds such as Resveratrol. Dr. Sinclair has been named as Time Magazine’s Top 100 Most Influential People in the World in 2014.

Jupiter Orphan Pharmaceuticals, Inc., www.jupiterorphan.com, was formed to address rare diseases caused by, or related to, single gene deficiencies.

Visit www.jupiterorphan.com for additional company information.

Media contact:



Christer Rosén, Jupiter Orphan Therapeutics - +1 561 308-7780
c.rosen@jupiterorphan.com